Advanced Geriatric Evaluation in predicting long term health related quality of life in elderly patients with ColoRectal Cancer

Published: 07-07-2017 Last updated: 13-04-2024

1. To determine the predictive value of frailty characteristics for loss of HRQL in elderly patients with non-metastatic CRC.2. To develop an AGE-CRC score, a prediction model for loss of HRQL in elderly patients with CRC based on comorbidity, risk...

Ethical review Approved WMO

Status Recruitment stopped

Health condition type Gastrointestinal neoplasms malignant and unspecified

Study type Observational non invasive

Summary

ID

NL-OMON46313

Source

ToetsingOnline

Brief title

AGE-CRC

Condition

- Gastrointestinal neoplasms malignant and unspecified
- Gastrointestinal therapeutic procedures

Synonym

fragile, frailty, vulnerability

Research involving

Human

Sponsors and support

Primary sponsor: Sint Antonius Ziekenhuis

Source(s) of monetary or material Support: St. Antonius Ziekenhuis en VIOZ(stichting

Vrienden Intergrale Oncologische Zorg)

Intervention

Keyword: Colorectal cancer, Geriatric assessment, Preoperative assessment

Outcome measures

Primary outcome

Primary endpoint is a loss of HRQL * 10 points(EORTC-QLQ-C30) at 12 months after CRC diagnosis.

Secondary outcome

Secondary endpoints are: HRQL after 3 and 6 months (EORTC-QLQ-C30/CR29), disability free survival after 3, 6 and 12 months (EQ-5D), postoperative complications during hospitalisation, number of hospital (re)admissions and outpatient visits during the study period, number of unexpected intensive care admissions, 30 days and 1 year mortality.

Study description

Background summary

Colorectal cancer (CRC) disproportionately affects patients aged 70 years and older. Surgery is the main treatment modality for CRC, but is associated with increased risk of postoperative morbidity, disability and loss of health related quality of life (HRQL). Frailty is an age related state of functional decline and considered to be an important risk factor for adverse outcome in geriatric oncology. Risk models for adverse outcome may be used for treatment decisions in the elderly, but are often not designed to predict patient related outcome measures and do not include frailty characteristics.

Study objective

2 - Advanced Geriatric Evaluation in predicting long term health related quality of ... 3-05-2025

- 1. To determine the predictive value of frailty characteristics for loss of HRQL in elderly patients with non-metastatic CRC.
- 2. To develop an AGE-CRC score, a prediction model for loss of HRQL in elderly patients with CRC based on comorbidity, risk factors and frailty.

Study design

Multicentre, prospective, observational cohort study with a follow up time of one year. After initial diagnosis of CRC subjects will be screened for frailty using validated questionnaires, physical tests and non-invasive measurements. Frailty characteristics and HRQL are determined by Geriatric 8 (G8), Hospital Anxiety and Depression Scale(HADS), Euroqol- 5 dimensional (EQ-5D), Lawton Instrumental Activities of Daily Living scale(IADL), Mini Nutrition Assessment (MNA), 6 Item Cognitive Impairment Test (6-CIT), Identification of Seniors At Risk * Hospitalized Patients(ISAR-HP) and the EORTC-QLQ-C30/CR29 (HRQL in CRC patients). Physical tests include the Timed to Get Up (TUG) test and the hand grip strength test. Furthermore, the non-invasive measurements consist of a sarcopenia analysis using an existing CT/MRI scan and measurement of Advanced Glycation Endproducts (AGE reader).

Additional patients characteristics including medication use, medical history and laboratory results of preoperative routine blood sampling will be collected. At three, six and twelve months after surgery or diagnosis, EORTC QLQ-C30/EORTC QLQ-CR29 and EQ-5D questionnaires are used to determine HRQL and disability free survival.

Study burden and risks

Frailty screening will be performed in all study patients with a new diagnosis of non-metastatic CRC and will approximately take 40 minutes per patient. This is an observational study, there are no expected risks associated with frailty screening. Participation in this study will not conflict with standard care and will not delay diagnosis or treatment. There is no individual benefit for the participating subjects. Currently little is known about the relation between frailty and HRQL after CRC surgery/diagnosis. No risks are expected as the subjects will be treated similar to patients who dot no participate. If this study shows that a risk model including frailty characteristics is predictive for loss of HRQL after CRC surgery, implementation of this model (after validation) in standard care should be considered.

Contacts

Public

Sint Antonius Ziekenhuis

Koekoekslaan 1 Koekoekslaan 1 Nieuwegein 3430 EM NL

Scientific

Sint Antonius Ziekenhuis

Koekoekslaan 1 Koekoekslaan 1 Nieuwegein 3430 EM NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Age * 70 years Histologically proven non-metastatic colorectal cancer

Exclusion criteria

Emergency surgery
Insufficient understanding of the Dutch language

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Basic science

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 31-08-2017

Enrollment: 340

Type: Actual

Ethics review

Approved WMO

Date: 07-07-2017

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 03-08-2017

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 05-10-2017

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL61523.100.17